Objectives-To determine daily production of nitric oxide (NO) measured as urinary nitrate excretion, and the effect of prednisolone in patients with rheumatoid arthritis (RA). Methods-Twenty four hour urinary nitrate was measured by gas chromatography in 10 patients with RA, before and two to four weeks after commencement of prednisolone 0 5 mg/kg body weight, and in 18 healthy controls. Results-Before the start of prednisolone treatment the urinary nitrate excretion in patients with RA was 2*7-fold greater (p < 0.001) than that in healthy volunteers.
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After prednisolone it decreased significantly, by 28%, at which time inflammatory activity (as indicated by C reactive protein, erythrocyte sedimentation rate, joint count, and early morning stiffness) was also reduced considerably. Despite this decrease, the urinary nitrate excretion in patients with RA remained twice that in the control group (p < 0 05). Conclusion-Our data suggest that the endogenous production ofNO is enhanced in patients with RA. Furthermore, the results indicate that, in parallel with suppression of inflammation, this increased NO synthesis could be reduced by prednisolone treatment.
(Ann Rheum Dis 1995; 54: 820-824) vascular tone,'0 platelet aggregation"' and neuronal signal transduction;'2 these actions are mediated by activation of soluble guanylate cyclase, followed by increased concentrations of cyclic guanosine monophosphate. "3 Little is known about the importance of the NO pathway in inflammatory joint diseases.
Studies in experimental adjuvant arthritis'4 1 ' and streptococcal cell wall induced arthritis '6 suggested increased endogenous NO synthesis in inflammatory joint diseases. In man, Farrell et al'7 reported increased concentrations of nitrite, a metabolite of NO, in serum and synovial fluid of patients with RA. NO itself is difficult to measure directly in vivo, because it is readily oxidised to nitrite and nitrate,'8 which are excreted rapidly into the urine. This endogenous nitrate synthesis explains the finding, made before discovery of the NO pathway, that people taking diets low in nitrate excrete four fold more nitrate in the urine than the amount ingested in their diet. '9 Furthermore, only 40-60% of the ingested nitrate appeared in urine,'9 20 which helps to explain why people taking a diet high in nitrate excrete less nitrate in the urine than they ingest. '9 (28) mm/lst h, joint count 20 (6) , and early morning stiffness 4 (2) h). Tables 1 and 2 summarise the epidemiological, drug treatment, clinical, and laboratory data of each patient. A control group comprised 18 healthy volunteers (house staff and honorary house The most important potential biasing factor in the evaluation of NO synthesis by measurement ofNO metabolites in body fluids is excess dietary intake of nitrite or nitrate. Our study groups were not subjected to a standardised diet, but excess dietary nitrite/nitrate intake was excluded. In the absence of intake in excess, dietary nitrite/nitrate contributes to urinary nitrate excretion to only a minor degree compared with endogenously generated nitrate. '9 21 The biasing effects of diet should therefore be insignificant, and the increased urinary nitrate excretion of our patients with RA may be assumed to indicate increased synthesis ofNO. Two of the 18 control subjects also had high urinary nitrate excretions (271 and 164 ,umol/mmol creatinine, respectively), but as they showed no recognisable differences compared with the other individuals in the control group (dietary nitrate/nitrite intake, health status, or drug treatment), they were included in the analysis.
Despite the clear evidence that NO plays a part in RA, the question remains whether NO is proinflammatory or anti-inflammatory. Current opinion is that large quantities of NO produced by the inducible NO synthase are cytotoxic and proinflammatory, whereas the low amounts of NO generated by the constitutive NO synthases are anti-inflammatory.3'
Physiological amounts of NO produced by endothelial cells have been shown to reduce adhesion and emigration of granulocytes,32 and in a mouse model of hepatic damage, inhibition of NO synthesis increased liver injury, suggesting a protective role for NO in this model. 33 In contrast, experiments in rats with adjuvant arthritis (a widely used animal model of RA) suggested a proinflammatory role of NO: competitive inhibitors of NO synthase, such as N0-nitro-L-arginine methyl ester or NG-mono-methyl-L-arginine (L-NMA), suppressed the development of the disease and reduced its severity, respectively; concomitant treatment with L-arginine, the substrate of NO synthase, abolished these effects.'4 34 35 Stefanovic-Racic et a135 determined urinary nitrate excretion, the parameter of interest in our study, in adjuvant arthritic rats; urinary nitrate excretion, which increased as the arthritis progressed, and disease activity were both inhibited by L-NMA in a dose dependent manner. In another animal model of arthritis, induced by intraperitoneal injection of streptococcal cell wall fragments in rats, administration of L-NMA profoundly reduced synovial inflammation, tissue damage, and NO production by synovial tissue. '6 In the present study, treatment with prednisolone, which is known to inhibit induction of the inducible NO synthase,36 reduced urinary nitrate excretion in parallel with disease activity. This may be suggestive of proinflammatory properties of NO, though the wide pharmacological effects of prednisolone and the complexity of NO actions allow no definite conclusion. Further human studies with in vivo use of specific inhibitors of the inducible NO synthase are required to elucidate the pathophysiological role of NO inflammatory joint diseases.
